Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention 300U Tubeless Patch Pump, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention TouchCare Nano System, all published on July 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about TouchCare Nano System
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention 300U Tubeless Patch Pump, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention TouchCare Nano System, all published on July 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering TouchCare Nano System. Shared-story counts are live from our verified record — not editorial picks.
Medtrum is advancing its 300U tubeless insulin pump toward the German market, leveraging its in-house APGO automated insulin delivery algorithm. The device’s reimbursement listing in Germany could pressure competitors like Insulet and Medtronic in the automated diabetes management space. Biopharma investors should watch for clinical evidence and partnership developments.